Tryptamine Therapeutics Advances Psilocin-Based IV Infusion To Phase 2 Clinical Trials
Tryptamine Therapeutics Advances Psilocin-Based IV Infusion To Phase 2 Clinical Trials
Armed with a robust proprietary dataset, Tryptamine is preparing to advance TRP-8803 to active patient studies. Phase 2 trials will target specific therapeutic indications, with planning already underway. Carroll highlighted the importance of these findings, stating, "Tryp has now established the strong foundations essential to advance our world-first trials for IV-infused psilocin to the highest standards of safety, quality and integrity."Tryptamine Therapeutics Ltd (OTC:TYPTF) has announced that its lead asset, TRP-8803, a psilocin-based IV infusion, will progress to Phase 2 clinical trials following a successful Phase 1b study. TRP-8803 demonstrated significant advantages over oral psilocybin, including rapid onset, precise control of the psychedelic state and the ability to halt treatment if adverse events occur, enhancing patient safety.
Tryptamine Therapeutics Ltd (OTC:TYPTF)宣布，其主力资产TRP-8803，一种基于哌幻基的静脉注射液，将在成功进行第10亿阶段研究后进入第2期临床试验。TRP-8803相对口服哌喹比有显著优势，包括快速发作、对迷幻状态的精确控制以及在出现不良事件时停止治疗的能力，提高了患者的安全性。
Phase 1b Achievements
第10亿阶段成就
TRP-8803 was well-tolerated across all tested doses—low, mid and high—demonstrating its safety profile. The study identified optimal doses and infusion rates that maintained psilocin blood levels within the therapeutic range. Additionally, TRP-8803 achieved steady and controlled blood levels, outperforming oral psilocybin formulations in terms of consistency.
TRP-8803在所有经过测试的剂量（低、中、高）中都具有良好的耐受性，表现出其安全性。该研究确定了维持哌幻血药浓度在治疗范围内的最佳剂量和输注速率。此外，TRP-8803实现了稳定和受控的血药浓度，表现出在一致性方面优于口服哌喹制剂。
Participants experienced a rapid onset of the psychedelic state, much faster than the typical one- to two-hour delay with oral psilocybin. "To have achieved these positive results from our Phase 1b for TRP-8803 study so quickly has exceeded all expectations," said Tryptamine CEO Jason Carroll.
参与者体验到了快速的迷幻状态发作，比口服哌喹通常需要一到两个小时的延迟快得多。Tryptamine首席执行官杰森·卡罗尔表示：“能够如此迅速地从我们对TRP-8803进行的第10亿阶段研究中取得这些积极结果已经超出了所有的预期。”
Path To Phase 2
第2期之路
Armed with a robust proprietary dataset, Tryptamine is preparing to advance TRP-8803 to active patient studies. Phase 2 trials will target specific therapeutic indications, with planning already underway. Carroll highlighted the importance of these findings, stating, "Tryp has now established the strong foundations essential to advance our world-first trials for IV-infused psilocin to the highest standards of safety, quality and integrity."
凭借强大的专有数据集，Tryptamine正准备将TRP-8803推进至积极的患者研究。第2期试验将针对特定的治疗指标，计划已经在进行中。卡罗尔强调了这些发现的重要性，称：“Tryp现已确立了推进IV注射哌幻进行世界首例试验所必不可少的坚实基础，达到最高安全、质量和完整性标准。”
TRP-8803: A Transformative Approach
TRP-8803：一种变革性方法
TRP-8803 offers multiple advantages over traditional oral psilocybin. It provides faster onset, precise control over treatment duration and reversibility, enabling clinicians to halt therapy immediately if necessary. These features make the treatment safer and more commercially viable while reducing the overall duration of therapy. By promoting neuroplasticity, TRP-8803 aims to drive adaptive structural and functional changes in the brain, solidifying Tryptamine's position at the forefront of psychedelic medical innovation.
TRP-8803相对传统口服哌喹具有多重优势。它提供更快的发作时间、对治疗时间的精确控制和可逆性，使临床医生可以立即停止疗法。这些特点使治疗更安全、更具商业可行性，同时缩短了整体疗程时间。通过促进神经可塑性，TRP-8803旨在驱动大脑的适应性结构和功能变化，巩固Tryptamine在迷幻医学创新前沿的地位。
Cove imgage made with AI
使用人工智能制作的封面图像
